Alkermes (NASDAQ:ALKS) has entered
into a clinical research collaboration with Fred Hutchinson Cancer
Research Center for ALKS 4230, an immuno-oncology drug candidate.
The planned phase 2 multi-site trial, ION-01, is
designed to estimate the response rate to ALKS 4230 in combination with
the anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with advanced
or recurrent head and neck squamous cell cancer who did not achieve
complete remission with an anti-PD-(NYSE:L)1 antibody treatment.
Secondary objectives include evaluation of the
duration of response, progression-free survival, time to progression and
overall survival.
The study is expected to initiate in Q4 2019.
https://seekingalpha.com/news/3507185-alkermes-teams-fred-hutchinson-cancer-research-center-immuno-oncology-drug-candidate
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.